A new partnership between the National Skin Centre Singapore, Sanofi, and the Agency for Science, Technology, and Research (A*STAR) aims to advance the understanding and treatment of acne, a common yet often persistent skin condition.
The collaboration, formalized through a memorandum of understanding (MoU), will kick off with a Phase 1 clinical study in the second quarter of 2025. The trial will focus on patients with mild acne and is expected to provide valuable insights into potential new treatments.
Alongside the clinical trial, a translational study will also be conducted to identify key biological markers that contribute to the severity of acne. This research could pave the way for more targeted therapies in the future.
Acne, a chronic inflammatory skin condition, affects a vast number of individuals worldwide, with approximately 80% of teenagers and an increasing 40% of adults experiencing the condition. This new partnership seeks to address the growing need for more effective treatments for this widespread health issue.
Related topic:
Plum Launches Niacinamide Range with Playful New Campaign
Cistto Partners with Global Experts to Revolutionize Skincare
Oti Mabuse Shares Her Secret to Glowing Skin and Hair
